Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity

Journal of Biological Chemistry

Volumn 288, Issue 19, 2013, Pages 13455-13466

  Salzmann, Steffen ^a   Seher, Axel ^a   Trebing, Johannes ^a   Weisenberger, Daniela ^a   Rosenthal, Alevtina ^a   Siegmund, Daniela ^a   Wajant, Harald ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGONISTIC ACTIVITY; ANTAGONISTIC ACTIVITY; FIBROBLAST GROWTH FACTOR; FULL SPECTRUM; MEMBRANE-BOUND; THERAPEUTIC TARGETS;

BIOCHEMISTRY; BIOLOGY;

ANTIBODIES;

ALKALINE PHOSPHATASE; ENAVATUZUMAB; FC RECEPTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; MONOCLONAL ANTIBODY; P 4A8; PROTEIN G; PROTEIN P100; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIMERIZATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANTIBODIES; APOPTOSIS; NF-KAPPA B (NF-KB); TRAF; TUMOR NECROSIS FACTOR (TNF);

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BACTERIAL PROTEINS; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; INTERLEUKIN-8; MACACA FASCICULARIS; MICE; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84877697920     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.435917     Document Type: Article

References (43)

1. Winkles, J. A. (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7, 411-425
2. Kawakita, T., Shiraki, K., Yamanaka, Y., Yamaguchi, Y., Saitou, Y., Enokimura, N., Yamamoto, N., Okano, H., Sugimoto, K., Murata, K., and Nakano, T. (2004) Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem. Biophys. Res. Commun. 318, 726-733
3. Willis, A. L., Tran, N. L., Chatigny, J. M., Charlton, N., Vu, H., Brown, S. A., Black, M. A., McDonough, W. S., Fortin, S. P., Niska, J. R., Winkles, J. A., and Cunliffe, H. E. (2008) The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol. Cancer Res. 6, 725-734
4. Ikner, A., and Ashkenazi, A. (2011) TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J. Biol. Chem. 286, 21546-21554
5. Schneider, P., Schwenzer, R., Haas, E., Mühlenbeck, F., Schubert, G., Scheurich, P., Tschopp, J., and Wajant, H. (1999) TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur. J. Immunol. 29, 1785-1792
6. Wicovsky, A., Salzmann, S., Roos, C., Ehrenschwender, M., Rosenthal, T., Siegmund, D., Henkler, F., Gohlke, F., Kneitz, C., and Wajant, H. (2009) TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ. 16, 1445-1459
7. Roos, C., Wicovsky, A., Müller, N., Salzmann, S., Rosenthal, T., Kalthoff, H., Trauzold, A., Seher, A., Henkler, F., Kneitz, C., and Wajant, H. (2010) Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-κB pathway. J. Immunol. 185, 1593-1605
8. Meighan-Mantha, R. L., Hsu, D. K., Guo, Y., Brown, S. A., Feng, S. L., Peifley, K. A., Alberts, G. F., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Richards, C. M., and Winkles, J. A. (1999) The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J. Biol. Chem. 274, 33166-33176
9. Kamata, K., Kamijo, S., Nakajima, A., Koyanagi, A., Kurosawa, H., Yagita, H., and Okumura, K. (2006) Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J. Immunol. 177, 6433-6439
10. Perper, S. J., Browning, B., Burkly, L. C., Weng, S., Gao, C., Giza, K., Su, L., Tarilonte, L., Crowell, T., Rajman, L., Runkel, L., Scott, M., Atkins, G. J., Findlay, D. M., Zheng, T. S., and Hess, H. (2006) TWEAK is a novel arthritogenic mediator. J. Immunol. 177, 2610-2620
11. Desplat-Jégo, S., Creidy, R., Varriale, S., Allaire, N., Luo, Y., Bernard, D., Hahm, K., Burkly, L., and Boucraut, J. (2005) Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin. Immunol. 117, 15-23
12. Desplat-Jégo, S., Varriale, S., Creidy, R., Terra, R., Bernard, D., Khrestchatisky, M., Izui, S., Chicheportiche, Y., and Boucraut, J. (2002) TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J. Neuroimmunol. 133, 116-123
13. Mueller, A. M., Pedré, X., Kleiter, I., Hornberg, M., Steinbrecher, A., and Giegerich, G. (2005) Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 159, 55-65
14. Dohi, T., Borodovsky, A., Wu, P., Shearstone, J. R., Kawashima, R., Runkel, L., Rajman, L., Dong, X., Scott, M. L., Michaelson, J. S., Jakubowski, A., and Burkly, L. C. (2009) TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 136, 912-923
15. Kawashima, R., Kawamura, Y. I., Oshio, T., Son, A., Yamazaki, M., Hagiwara, T., Okada, T., Inagaki-Ohara, K., Wu, P., Szak, S., Kawamura, Y. J., Konishi, F., Miyake, O., Yano, H., Saito, Y., Burkly, L. C., and Dohi, T. (2011) Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 141, 2119-2129.e8
16. Zhao, Z., Burkly, L. C., Campbell, S., Schwartz, N., Molano, A., Choudhury, A., Eisenberg, R. A., Michaelson, J. S., and Putterman, C. (2007) TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 179, 7949-7958
17. Muñoz-García, B., Moreno, J. A., López-Franco, O., Sanz, A. B., Martín-Ventura, J. L., Blanco, J., Jakubowski, A., Burkly, L. C., Ortiz, A., Egido, J., and Blanco-Colio, L. M. (2009) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 29, 2061-2068
18. Schapira, K., Burkly, L. C., Zheng, T. S., Wu, P., Groeneweg, M., Rousch, M., Kockx, M. M., Daemen, M. J., and Heeneman, S. (2009) Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/-mice and inhibits macrophage lipid uptake in vitro. Arterioscler. Thromb. Vasc. Biol. 29, 2021-2027
19. Hotta, K., Sho, M., Yamato, I., Shimada, K., Harada, H., Akahori, T., Nakamura, S., Konishi, N., Yagita, H., Nonomura, K., and Nakajima, Y. (2011) Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int. 79, 179-188
20. Jakubowski, A., Ambrose, C., Parr, M., Lincecum, J. M., Wang, M. Z., Zheng, T. S., Browning, B., Michaelson, J. S., Baetscher, M., Baestcher, M., Wang, B., Bissell, D. M., and Burkly, L. C. (2005) TWEAK induces liver progenitor cell proliferation. J. Clin. Invest. 115, 2330-2340
21. Mittal, A., Bhatnagar, S., Kumar, A., Lach-Trifilieff, E., Wauters, S., Li, H., Makonchuk, D. Y., and Glass, D. J. (2010) The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. 188, 833-849
22. Potrovita, I., Zhang, W., Burkly, L., Hahm, K., Lincecum, J., Wang, M. Z., Maurer, M. H., Rossner, M., Schneider, A., and Schwaninger, M. (2004) Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J. Neurosci. 24, 8237-8244
23. Yepes, M., Brown, S. A., Moore, E. G., Smith, E. P., Lawrence, D. A., and Winkles, J. A. (2005) A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol. 166, 511-520
24. Michaelson, J. S., and Burkly, L. C. (2009) Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl. Cell Differ. 49, 145-160
25. Culp, P. A., Choi, D., Zhang, Y., Yin, J., Seto, P., Ybarra, S. E., Su, M., Sho, M., Steinle, R., Wong, M. H., Evangelista, F., Grove, J., Cardenas, M., James, M., Hsi, E. D., Chao, D. T., Powers, D. B., Ramakrishnan, V., and Dubridge, R. (2010) Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin. Cancer Res. 16, 497-508
26. Michaelson, J. S., Amatucci, A., Kelly, R., Su, L., Garber, E., Day, E. S., Berquist, L., Cho, S., Li, Y., Parr, M., Wille, L., Schneider, P., Wortham, K., Burkly, L. C., Hsu, Y. M., and Joseph, I. B. (2011) Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 3, 362-375
27. Tran, N. L., McDonough, W. S., Savitch, B. A., Fortin, S. P., Winkles, J. A., Symons, M., Nakada, M., Cunliffe, H. E., Hostetter, G., Hoelzinger, D. B., Rennert, J. L., Michaelson, J. S., Burkly, L. C., Lipinski, C. A., Loftus, J. C., Mariani, L., and Berens, M. E. (2006) Increased fibroblast growth factorinducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res. 66, 9535-9542
28. Culp, P. (2009) Therapeutic use of anti-TWEAK antibodies. WO2009020933A2
29. Garber, E., Burkly, L., Michealson, J., Lugovskoy, A., Hsu, Y.-M., and Hanf, K. (2009) Anti-Fn14 antibodies and uses thereof. WO2009140177A2
30. Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., Compaan, D., Lowman, H., Hymowitz, S., and Ashkenazi, A. (2008) Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 15, 751-761
31. Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., and Krammer, P. H. (1992) Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149, 3166-3173
32. Natoni, A., MacFarlane, M., Inoue, S., Walewska, R., Majid, A., Knee, D., Stover, D. R., Dyer, M. J., and Cohen, G. M. (2007) TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br. J. Haematol. 139, 568-577
33. Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., Ross, S., Vernes, J. M., Lu, Y., Adams, C., Offringa, R., Kelley, B., Hymowitz, S., Daniel, D., Meng, G., and Ashkenazi, A. (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101-113
34. Kanarek, N., and Ben-Neriah, Y. (2012) Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol. Rev. 246, 77-94
35. O'Donnell, M. A., and Ting, A. T. (2011) RIP1 comes back to life as a cell death regulator in TNFR1 signaling. FEBS J 278, 877-887
36. Razani, B., Reichardt, A. D., and Cheng, G. (2011) Non-canonical NF-κB signaling activation and regulation: principles and perspectives. Immunol. Rev. 244, 44-54
37. Vince, J. E., Chau, D., Callus, B., Wong, W. W., Hawkins, C. J., Schneider, P., McKinlay, M., Benetatos, C. A., Condon, S. M., Chunduru, S. K., Yeoh, G., Brink, R., Vaux, D. L., Silke, J. (2008) TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFα. J. Cell Biol. 182, 171-184
38. Ortiz, A., Sanz, A. B., Muñoz García, B., Moreno, J. A., Sánchez Niño, M. D., Martín-Ventura, J. L., Egido, J., and Blanco-Colio, L. M. (2009) Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine. Growth Factor. Rev. 20, 251-258
39. Park, Y. C., Burkitt, V., Villa, A. R., Tong, L., and Wu, H. (1999) Structural basis for self-association and receptor recognition of human TRAF2. Nature 398, 533-538
40. Ye, H., Park, Y. C., Kreishman, M., Kieff, E., and Wu, H. (1999) The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol. Cell 4, 321-330
41. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. (1998) NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683
42. Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G., and Wu, H. (2010) Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol. Cell 38, 101-113
43. Fick, A., Lang, I., Schäfer, V., Seher, A., Trebing, J., Weisenberger, D., and Wajant, H. (2012) Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J. Biol. Chem. 287, 484-495